Drug Profile
CSPCHA 115
Alternative Names: CSPCHA-115Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antiallergics; Antiasthmatics; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Allergic-rhinitis(In volunteers) in China (PO, Capsule)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (PO, Capsule)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Allergic-rhinitis in USA (PO, Capsule)